Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CREPT-618
- Development stage
- Phase 2
- Lead developer
- Heya
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
CREPT-618 is an investigational small nucleic acid therapeutic developed by Heya (Beijing) Pharmaceutical Technology in collaboration with the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. It is designed to target the Cell cycle Related and Expression-Elevated Protein in Tumor (CREPT), also known as RPRD1B (Regulation of nuclear pre-mRNA domain-containing protein 1B). CREPT is an oncogene that is frequently overexpressed in various malignancies and plays a critical role in promoting tumor growth by regulating the transcription of cell cycle-related genes, such as Cyclin D1, and modulating the Wnt/β-catenin signaling pathway. CREPT-618 utilizes RNA interference or a similar nucleic acid-based mechanism to silence the expression of this protein, thereby inhibiting tumor cell proliferation and progression. It is currently being evaluated in the PLATFORM2 Phase I/II clinical trial (NCT06264310) for patients with advanced rare solid tumors who have failed standard therapies.
- Other names
- CREPT-618 InjectionCREPT618 InjectionCREPT 618 Injection
02
Targets
TAGLN (Transgelin)
Beyond the preview
Go deeper on CREPT-618.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CREPT-618.